NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.
“Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid19 and has an overall efficacy of 89%. Hope to launch by September 2021!,” Poonawalla said in a tweet.
Covovax trials begin in India, hope to launch it by Sept 2021: Adar Poonawalla – Times of India
More from NewsMore posts in News »
- €500 million in private sector investments headed for Ukraine
- RBI asks banks to share information on exposure to Adani Group companies – Business Standard
- NSE puts some Adani firms under watch: What is additional surveillance mechanism (ASM)? – The Indian Express
- Hindenburg bet against India’s Adani puzzles rival U.S. short sellers – Reuters India
- Gautam Adani fails to calm investors as market wipeout hits $100 billion – CNN